Radioactive therapy targets Hard-to-Treat kidney cancer
NCT ID NCT06959433
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests a radioactive drug called Lu-177 PSMA in 20 people with metastatic clear cell kidney cancer that has worsened after at least two prior treatments. The drug is designed to seek out and destroy cancer cells while limiting damage to healthy tissue. Researchers will monitor side effects and measure tumor response using standard criteria.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lu-177 PSMA-617 (a radioactive drug that targets cancer cells)
What this could lead to
If it works, this could offer a new treatment option for people with advanced kidney cancer who have run out of standard therapies.
What could go wrong
This is a very small early-phase trial (only 20 people), so results may not apply to everyone. The treatment involves radiation, which can cause side effects like damage to kidneys, liver, or salivary glands.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CLEAR CELL RENAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••